|View printer-friendly version|
BEIJING, China, January 8, 2015 — BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced that John V. Oyler, Founder and Chief Executive Officer, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2015, at 4:00 p.m. Pacific Time (PT). BeiGene will also be participating in the following industry event panels in San Francisco:
- Biotech Showcase 2015 Lunch Plenary Session on Monday, January 12, 2015 at 12:00 p.m. PT
- WuXi Global Forum 2015: “A Celebration of Global Partnerships,” on Tuesday, January 13, 2015, at 5:00 p.m. PT
About BeiGene (Beijing), Co., Ltd.
BeiGene is an innovative, clinical-stage Chinese oncology R&D company focused on discovering, developing and commercializing targeted and immune-oncology therapeutics through a novel translational research platform that leverages our strong internal oncology biology expertise with unique access to large number of patientderived tumor biopsies. With a team of 150 scientists and staff, its pipeline is comprised of novel oral small molecules and monoclonal antibodies for cancer. BeiGene Ltd. is a Cayman Islands exempted company that is an investor in and collaborator with BeiGene (Beijing), Co. Ltd.
For more information, please visit our website at www.beigene.com.
Stern Investor Relations, Inc.